Growth Hormone Peptides: Sermorelin, Ipamorelin, CJC-1295

Informational only. Not medical advice. Sermorelin, ipamorelin, and CJC-1295 are not FDA-approved for anti-aging or performance use. Sermorelin's original approval (Geref) was withdrawn; the others sit on the FDA Category 2 compounding list as of June 2026. All are prohibited in sport by WADA. Do not start, stop, or change any treatment based on what you read here. Speak with a licensed clinician.

People comparing sermorelin, ipamorelin, and CJC-1295 want to know which growth-hormone peptide is best — and whether any are legal. All three are growth hormone secretagogues (GHS): they prompt your pituitary to release more of your own GH rather than injecting synthetic HGH. They differ in half-life, selectivity, and regulatory status. For how these compare to testosterone replacement, see our peptide therapy vs TRT comparison, and for the legal picture our peptide legality map 2026.

What is the difference between sermorelin, ipamorelin, and CJC-1295?

Sermorelin and CJC-1295 are GHRH analogs; ipamorelin is a ghrelin-receptor agonist (a GHRP). GHRH analogs and GHRPs act on different pituitary pathways, which is why CJC-1295 and ipamorelin are often paired. Sermorelin is a 29-amino-acid copy of natural growth hormone-releasing hormone — short-acting, cleared in minutes, so it's dosed daily. CJC-1295 is a modified GHRH analog; the "with DAC" version carries a Drug Affinity Complex that binds albumin and stretches its half-life to roughly 6-8 days, allowing once- or twice-weekly dosing. Ipamorelin mimics ghrelin at the GH-secretagogue receptor and triggers a clean GH pulse. GHRH primes the pituitary; the GHRP pulses it — combined, they produce a larger release than either alone.

Which growth hormone peptide is best?

There's no single winner — the right choice depends on the goal and the prescriber's judgment. Sermorelin produces the most physiologic, pulse-like GH release and has the longest clinical track record, which is why it's often the conservative starting point. Ipamorelin's edge is selectivity: unlike older GHRPs (GHRP-6, hexarelin), it raises GH without meaningfully bumping cortisol, prolactin, or appetite, so side effects tend to be milder. CJC-1295 wins on convenience and sustained elevation thanks to its long half-life. The CJC-1295 + ipamorelin pair is the most prescribed combination because the two mechanisms stack — a sustained GHRH background plus a sharp ghrelin-driven pulse.

Are these peptides FDA-approved?

No — none are FDA-approved for anti-aging or performance use as of June 2026. Sermorelin was once FDA-approved as Geref for pediatric growth hormone deficiency, but the manufacturer discontinued it; it survives only through compounding pharmacies with a prescription. Ipamorelin and CJC-1295 were never approved and sit on the FDA's Category 2 "do not compound" list, with a February 27, 2026 HHS announcement signaling possible reclassification that has not yet been formalized. All three require a prescription, and all are prohibited at all times in sport under the WADA peptide-hormone and growth-factor categories.

How does growth hormone decline with age?

GH output falls roughly 14% per decade after the 30s, a process called somatopause. Growth hormone is released in pulses, mostly during deep slow-wave sleep, and both pulse height and frequency drop with age. That decline tracks with changes in body composition, recovery, and sleep quality — the rationale GHS therapy is built on. The premise is restoration of a more youthful secretion pattern rather than flooding the body with exogenous hormone, which is why these peptides preserve the pituitary's own feedback loops better than synthetic HGH.

<a id="comparison-table"></a>

Head-to-head: sermorelin vs ipamorelin vs CJC-1295

Dimension	Sermorelin	Ipamorelin	CJC-1295 (with DAC)
Class	GHRH analog	GHRP (ghrelin-receptor agonist)	GHRH analog + albumin binder
Sequence	29-amino-acid GHRH (1-29)	Synthetic pentapeptide	Modified GHRH 1-29 + DAC
Mechanism	Primes pituitary GH release	Pulses GH via ghrelin receptor	Sustained GHRH stimulation
Half-life	~10-20 minutes	~2 hours	~6-8 days
Typical frequency	Daily	Daily / 5-days-on	1-2x per week
Selectivity	GH only	High — minimal cortisol/prolactin	GH only
Raises appetite?	No	Minimal	No
FDA status	Approval withdrawn (was Geref); compounded only	Not approved; Category 2	Not approved; Category 2
WADA / sport	Prohibited at all times	Prohibited at all times	Prohibited at all times
Best paired with	Often standalone	CJC-1295	Ipamorelin
Common role	Conservative, physiologic starting point	Clean pulse, mild side effects	Convenience, sustained elevation

The table is the headline. Mechanism and safety detail follow.

How does sermorelin work?

Sermorelin is a synthetic copy of the first 29 amino acids of GHRH — the active region. It binds GHRH receptors on the anterior pituitary and prompts release of the body's own growth hormone. Because it's short-acting and works with natural feedback, it tends to produce a physiologic, pulse-like GH profile rather than a flat elevation. The most common benefits patients report are improved sleep depth (GH peaks during slow-wave sleep), better recovery, and gradual body-composition shifts. The trade-off is daily dosing and a slower, subtler effect than synthetic HGH.

How do ipamorelin and CJC-1295 work together?

Ipamorelin and CJC-1295 hit two different levers, which is why clinics pair them. CJC-1295 keeps a steady GHRH-style signal on the pituitary thanks to its albumin-bound, multi-day half-life. Ipamorelin then triggers a sharp, selective GH pulse through the ghrelin receptor — without the cortisol and prolactin bumps that plague older GHRPs. The 2006 JCEM study by Ionescu and Goujon found CJC-1295 produced sustained, dose-dependent increases in GH and IGF-1 in healthy adults. Combined, the pair mimics a more robust natural secretion pattern than either peptide alone.

What are the side effects of growth hormone peptides?

GHS side effects are usually mild and dose-dependent: injection-site redness, transient water retention, occasional headache, flushing, or dizziness. Because they raise GH and downstream IGF-1, the same cautions that apply to GH therapy apply here — fluid retention, possible effects on insulin sensitivity and blood glucose, and joint or carpal-tunnel discomfort at higher doses. An underactive thyroid can blunt the response, so thyroid status should be stabilized first. The theoretical IGF-1/cancer question that shadows all GH-axis therapy means age-appropriate screening matters. For the full risk breakdown across peptide classes, see our peptide therapy side effects guide.

Frequently asked questions

What is the difference between sermorelin and CJC-1295? Both are GHRH analogs, but sermorelin is short-acting (cleared in minutes, dosed daily) while CJC-1295 with DAC binds albumin and lasts roughly 6-8 days, allowing weekly dosing. Sermorelin produces a more physiologic pulse pattern; CJC-1295 produces a sustained elevation. Sermorelin was once FDA-approved (Geref) but is now compounded only; CJC-1295 was never approved.

Is ipamorelin better than CJC-1295? They do different jobs, which is why they're usually combined rather than compared. Ipamorelin is a ghrelin-receptor agonist that delivers a clean, selective GH pulse with minimal cortisol or prolactin effects. CJC-1295 is a long-acting GHRH analog that keeps the pituitary primed. Together they produce a larger GH release than either alone.

Are growth hormone peptides FDA-approved? No. Sermorelin's original approval (Geref) was withdrawn and it now exists only through compounding pharmacies. Ipamorelin and CJC-1295 were never FDA-approved and sit on the FDA Category 2 compounding list as of June 2026. All require a prescription, and all are banned in sport by WADA.

Do growth hormone peptides actually raise GH? Yes — these peptides stimulate the pituitary to release more of the body's own growth hormone, and CJC-1295 has human trial data (Ionescu and Goujon, 2006) showing sustained GH and IGF-1 increases. The effect is more modest and physiologic than injecting synthetic HGH, and individual response varies.

Which growth hormone peptide is safest? No peptide is risk-free, but ipamorelin is often described as the gentlest because of its selectivity — it raises GH without the cortisol, prolactin, and appetite spikes seen with older GHRPs. Sermorelin's long clinical history also makes it a conservative choice. Safety depends heavily on prescriber monitoring and sourcing from a licensed compounding pharmacy.

Related Reading

• Peptide therapy vs TRT (2026): mechanism, cost, and evidence
• Tesamorelin vs CJC-1295 for body composition (2026)
• Peptide therapy side effects and risks (2026)
• Peptide legality map 2026: what's legal, banned, and gray area

---

-- The Peptide Front Team